Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial.

Idorn T, Knop FK, Jørgensen MB, Jensen T, Resuli M, Hansen PM, Christensen KB, Holst JJ, Hornum M, Feldt-Rasmussen B

Diabetes care17 Aug 2015Cited by 74 (Europe PMC)

PMID26283739DOI10.2337/dc15-1025PepBankPUB-26283739

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialPharmacokinetics
In patients with type 2 diabetes, dose-corrected trough liraglutide concentration was 49% higher in patients with ESRD than in control subjects with normal kidney function.
In plain wordsIn people with type 2 diabetes, liraglutide blood levels were higher in those on dialysis than in those with normal kidney function.
Peptide
Liraglutide
Outcome
IncreaseDose-corrected plasma trough liraglutide concentration
Study
n: not reported in source
Comparator
Control subjects with normal kidney function
Analysis
Primary
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
titrated to a maximum of 1.8 mg · subcutaneous · 12 weeksAs given in this study (human).
Measurements
trough concentration increase
49%
ESRD versus control
Source sentences
Summary
Dose-corrected plasma trough liraglutide concentration at the final visit was increased by 49% (95% CI 6-109, P = 0.02) in the group with ESRD compared with the control group.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-four patients with type 2 diabetes and ESRD and 23 control subjects with type 2 diabetes and normal kidney function were randomly allocated to 12 weeks of double-blind liraglutide (titrated to a maximum dose of 1.8 mg) or placebo treatment (1:1) injected subcutaneously once daily as add on to…
Report a problemFND-2628373901
02HumanRandomized controlled trialSafety outcome
In patients with type 2 diabetes treated with liraglutide, initial and temporary nausea was more frequent in patients with ESRD than in control subjects.
In plain wordsIn people with type 2 diabetes on liraglutide, early nausea was more common in those on dialysis than in those with normal kidney function.
Peptide
Liraglutide
Outcome
IncreaseNausea
Study
n: not reported in source
Comparator
Control subjects with normal kidney function
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
titrated to a maximum of 1.8 mg · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Initial and temporary nausea and vomiting occurred more frequently among liraglutide-treated patients with ESRD compared with control subjects (P < 0.04).
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-four patients with type 2 diabetes and ESRD and 23 control subjects with type 2 diabetes and normal kidney function were randomly allocated to 12 weeks of double-blind liraglutide (titrated to a maximum dose of 1.8 mg) or placebo treatment (1:1) injected subcutaneously once daily as add on to…
Report a problemFND-2628373902
03HumanRandomized controlled trialSafety outcome
In patients with type 2 diabetes treated with liraglutide, initial and temporary vomiting was more frequent in patients with ESRD than in control subjects.
In plain wordsIn people with type 2 diabetes on liraglutide, early vomiting was more common in those on dialysis than in those with normal kidney function.
Peptide
Liraglutide
Outcome
IncreaseVomiting
Study
n: not reported in source
Comparator
Control subjects with normal kidney function
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
titrated to a maximum of 1.8 mg · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Initial and temporary nausea and vomiting occurred more frequently among liraglutide-treated patients with ESRD compared with control subjects (P < 0.04).
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-four patients with type 2 diabetes and ESRD and 23 control subjects with type 2 diabetes and normal kidney function were randomly allocated to 12 weeks of double-blind liraglutide (titrated to a maximum dose of 1.8 mg) or placebo treatment (1:1) injected subcutaneously once daily as add on to…
Report a problemFND-2628373903
04HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes with and without ESRD, glycemic control tended to improve during liraglutide treatment in both groups.
In plain wordsIn people with type 2 diabetes, with or without dialysis, blood sugar control tended to improve during liraglutide treatment.
Peptide
Liraglutide
Outcome
DecreaseGlycemic control (daily blood glucose)
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
titrated to a maximum of 1.8 mg · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Glycemic control tended to improve during the study period in both liraglutide-treated groups as assessed by daily blood glucose measurements (P < 0.01)
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-four patients with type 2 diabetes and ESRD and 23 control subjects with type 2 diabetes and normal kidney function were randomly allocated to 12 weeks of double-blind liraglutide (titrated to a maximum dose of 1.8 mg) or placebo treatment (1:1) injected subcutaneously once daily as add on to…
Report a problemFND-2628373904
05HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes with and without ESRD, the dose of baseline insulin was reduced during liraglutide treatment.
In plain wordsIn people with type 2 diabetes, with or without dialysis, the need for background insulin fell during liraglutide treatment.
Peptide
Liraglutide
Outcome
DecreaseDose of baseline insulin
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
titrated to a maximum of 1.8 mg · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Glycemic control tended to improve during the study period in both liraglutide-treated groups as assessed by daily blood glucose measurements (P < 0.01), and dose of baseline insulin was reduced in parallel (P < 0.04).
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-four patients with type 2 diabetes and ESRD and 23 control subjects with type 2 diabetes and normal kidney function were randomly allocated to 12 weeks of double-blind liraglutide (titrated to a maximum dose of 1.8 mg) or placebo treatment (1:1) injected subcutaneously once daily as add on to…
Report a problemFND-2628373905
06HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and ESRD, body weight fell by 2.4 kg with liraglutide, a change that was not significant.
In plain wordsIn people with type 2 diabetes on dialysis, liraglutide treatment was followed by a small weight loss that was not statistically significant.
Peptide
Liraglutide
Outcome
No significant changeBody weight change in patients with ESRD
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
titrated to a maximum of 1.8 mg · subcutaneous · 12 weeksAs given in this study (human).
Measurements
body weight change
−2.4 kg
ESRD, liraglutide
Source sentences
Summary
Body weight was reduced in both liraglutide-treated groups (-2.4 ± 0.8 kg [mean ± SE] in the group with ESRD, P = 0.22; -2.9 ± 1.0 kg in the control group, P = 0.03).
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-four patients with type 2 diabetes and ESRD and 23 control subjects with type 2 diabetes and normal kidney function were randomly allocated to 12 weeks of double-blind liraglutide (titrated to a maximum dose of 1.8 mg) or placebo treatment (1:1) injected subcutaneously once daily as add on to…
Report a problemFND-2628373906
07HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and normal kidney function, body weight fell significantly by 2.9 kg with liraglutide.
In plain wordsIn people with type 2 diabetes and normal kidney function, liraglutide treatment was followed by weight loss.
Peptide
Liraglutide
Outcome
DecreaseBody weight change in control subjects
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
titrated to a maximum of 1.8 mg · subcutaneous · 12 weeksAs given in this study (human).
Measurements
body weight change
−2.9 kg
control, liraglutide
Source sentences
Summary
Body weight was reduced in both liraglutide-treated groups (-2.4 ± 0.8 kg [mean ± SE] in the group with ESRD, P = 0.22; -2.9 ± 1.0 kg in the control group, P = 0.03).
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-four patients with type 2 diabetes and ESRD and 23 control subjects with type 2 diabetes and normal kidney function were randomly allocated to 12 weeks of double-blind liraglutide (titrated to a maximum dose of 1.8 mg) or placebo treatment (1:1) injected subcutaneously once daily as add on to…
Report a problemFND-2628373907

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 completed · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 2NCT04529278

Efficacy and Tolerance of Liraglutide for Weight Loss in Obese Type 2 Diabetic Hemodialysis Patients

Fondation Hôpital Saint-Josephn = 1818 Jan 2021 to est. 31 Dec 2023

Diabetes Mellitus, Type 2 · Hemodialysis · Obese

Trial page ClinicalTrials.govUpdated 14 Apr 2023

CompletedPhase 4NCT01394341

Liraglutide Treatment to Patients With Severe Renal Insufficiency

Bo Feldt-Rasmussenn = 40Sept 2011 to Oct 2013

Type 2 Diabetes Mellitus · End-stage Renal Disease

Trial page ClinicalTrials.govUpdated 9 Oct 2013

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.